Misplaced Lens Cap
tannertan36
No title available
TVSTRANGERTHINGS
todays bird
taylor price
trying on a metaphor
YOU ARE THE REASON
@theartofmadeline
Love Begins
Andulka
No title available
No title available
Alisa U Zemlji Chuda
祝日 / Permanent Vacation
No title available
occasionally subtle
hello vonnie
Peter Solarz
$LAYYYTER
seen from Italy
seen from United States
seen from United States
seen from Brazil
seen from Canada
seen from Finland
seen from United Kingdom
seen from Germany
seen from United Kingdom
seen from United States
seen from Romania
seen from United States
seen from Estonia
seen from United Kingdom
seen from Malaysia
seen from Malaysia
seen from United States
seen from United States
seen from United States
seen from Türkiye
@jeffreygoffman
A Look at StrideCare's Recent Expansion Efforts
Already the largest multi-specialty physician group for lower extremity care in Texas, StrideCare has recently initiated multiple strategic partnerships to strengthen its presence in the state and expand nationwide. In April 2026, the group finalized a strategic partnership with Texas Vascular Institute. In 2025, StrideCare partnered with the South Carolina-based Coastal Vascular & Vein…
How a Multidisciplinary Care Team Improves Patient Outcomes
Modern healthcare often involves conditions that no single professional can manage alone. A multidisciplinary care team brings together physicians, nurses, pharmacists, therapists, social workers, and other specialists who contribute diverse expertise. Groups such as StrideCare show how coordinated specialists can work together to address complex patient needs through a team-based model. Instead…
How CureDuchenne Funds Ideas Before Large Investors Step In
Rare disease research often moves more slowly than families would like. Small patient populations and scientific uncertainty make it harder to build strong evidence, even when early laboratory results look promising. Government reviews typically require structured submissions and follow-up data before a therapy can advance under defined conditions. Public reporting from patient groups and…
Understanding Duchenne Muscular Dystrophy
CureDuchenne is a global leader in areas of research, patient care, and innovation for enhancing and extending the lives of individuals living with Duchenne muscular dystrophy, more commonly known as Duchenne or DMD. Duchenne is one of over 30 genetic conditions in the muscular dystrophy family characterized by muscle weakness and other symptoms that affect the muscles. The National Institute of…
Cardinal Health Completes Acquisition of Integrated Oncology Network, Founded by Jeffrey Goffman
ION accelerates development of Navista, integrating more than 100 providers at more than 50 community-based sites across 10 states into oncology practice alliance. Cardinal Health (NYSE: CAH) announced today that it has completed its acquisition of Integrated Oncology Network (ION), a physician-led independent community oncology network co-founded by Jeffrey Goffman in 2008. Under Goffman’s…
My Houston Surgeons Joins the ARSA Network
The Advanced Reconstructive Surgery Alliance (ARSA) offers cosmetic and reconstructive surgeons throughout the United States a full suite of services to facilitate business growth. ARSA also supports unaffiliated medical professionals with back-office administration and insurance coordination services, marketing, human resources, and more. In March 2024, ARSA added another reconstructive surgery…
View On WordPress
How Hospital Joint Ventures Are Transforming the Industry
Hospital joint ventures are reshaping the healthcare industry by fostering partnerships that address operational, financial, and service delivery challenges. In an increasingly complicated healthcare sector, these alliances among hospitals, corporate corporations, and other healthcare institutions have enabled innovation and efficiency. Joint ventures strategically respond to changing patient and…
View On WordPress
Treatments for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive genetic condition predominantly affecting boys and men, characterized by a gradual loss of muscle function over time. Although present from birth, symptoms typically manifest in early childhood. Current treatment options for DMD focus on slowing disease progression and managing associated symptoms, such as muscle tightness, cardiovascular issues, and respiratory problems.
Steroid therapy is a primary treatment approach for DMD. Physicians often prescribe corticosteroids to patients, aiming to boost muscle strength and delay the loss of mobility by up to two to three years. Steroids also help reduce the risk of spinal curvature and enhance breathing function in individuals with DMD. Initiating steroid treatment early in the disease course tends to yield better outcomes.
Exon-skipping drugs represent another standard therapy for DMD. These medications target the genetic mutations underlying the condition, aiming to promote the production of functional dystrophin proteins. However, this treatment approach is effective for only a subset of individuals with DMD.
Management of DMD may also involve addressing conditions such as sideways spinal curvature, known as scoliosis, which often arises as the disease progresses. Physicians monitor scoliosis using X-rays to determine the need for interventions such as braces or vests. In severe cases where spinal curvature impacts heart or breathing function, surgical intervention may be necessary.
Progress and Support for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the absence of a protein called dystrophin. It primarily affects boys, with symptom onset usually occurring between ages two and three. DMD leads to muscle weakness, making running, jumping, and walking challenging. Other symptoms include enlarged calves, a waddling gait, and inward spinal curvature.
Research has made strides since its discovery in the 1860s. Understanding the genetic cause paved the way for innovative approaches like CureDuchenne Link®, a data-integrated biobank aimed at accelerating research and improving care. Collecting biosamples and participant data provides a comprehensive resource for researchers working toward a cure. Participation is open to individuals living in the United States affected by DMD or Becker Muscular Dystrophy, regardless of mutation.
Every mutation matters in advancing research and developing effective therapies. CureDuchenne Link's community-centric approach and seamless participant experience contribute to a holistic understanding of the conditions, facilitating progress toward treatments and, ultimately, a cure.
The Work of CureDuchenne
CureDuchenne is a nonprofit dedicated to saving the lives of boys with Duchenne muscular dystrophy (DMD). DMD belongs to a category of medical conditions called muscular dystrophies, a group of genetic disorders where muscles experience weakness. DMD complicates even the most basic activities. In addition, as the condition progresses, the muscles responsible for heart and breathing functions are also affected, further weakening the body.
This medical condition mostly affects boys. By age 12, most of them start to experience social isolation. Studies report that most boys with DMD do not make it to their late twenties, and those who do are usually confined to a wheelchair. There are about 20,000 boys living with DMD in the US, and more than 300,000 worldwide.
CureDuchenne is a renowned global innovation, research, and patient care organization committed to developing medical solutions that can improve and extend the lives of boys living with DMD. Together with its board of directors and scientific advisory board, the organization’s activities include extending patient ambulation in partnership with healthcare and medical professionals and pharmaceutical companies. Ambulation refers to the ability to walk without needing any assistance.
CureDuchenne’s diverse efforts include focusing on DMD treatments, investing in companies pursuing dystrophin-restoring and anti-inflammatory approaches. Dystrophin is the protein that stabilizes muscles.
The organization also seeks innovative technologies to overcome current therapy limitations. CureDuchenne Ventures’ investments have attracted over $3 billion in financing, leading to successful exits with venture capital, biotech, and pharmaceutical partners.
What You Should Know about Podiatry
Podiatry, also called podiatric medicine and surgery, is a branch of medicine dealing with studying, diagnosing, and treating ankle and foot disorders. A specialist practicing podiatry is called a podiatrist. Notably, their official title is doctor of podiatric medicine (DPM). Additionally, they attend specialized schools and belong to distinct professional associations, not following the traditional medical school path.
Podiatrists treat people of varying ages for foot-related medical conditions. These include conditions such as arthritis, fractures and sprains, heel pains, and diabetes-related foot and leg nerve damage. Other conditions they treat include bunions, hammertoes, and Morton’s neuroma.
A bunion forms when the joint at the big toe’s base enlarges or dislocates, causing the toe to bend toward other toes. A hammertoe is an improperly bending toe. Morton’s neuroma is a pain or burning sensation arising from nerve issues between the third and fourth foot bones, common in runners. Tight shoes can also lead to this condition.
Aside from diagnosing and treating common foot and leg conditions, podiatrists can diagnose and treat foot and leg-related nail and skin diseases, deformities, tumors, and ulcers. Also, they develop flexible casts that provide steady support to the feet and legs for injuries like fractures and sprains.
Additionally, they discuss preventive foot care with patients. Moreover, if foot symptoms suggest disorders in other body systems, a podiatrist may facilitate referrals to other specialists.
CureDuchenne Lauds FDA’s Approval of AGAMREE
CureDuchenne, a charitable organization that funds research efforts for the early diagnosis and treatment of Duchenne muscular dystrophy, lauded the US Food and Drug Administration for its AGAMREE (vamorolone) approval. CureDuchenne was involved during the early development stage of AGAMREE when it recognized that the drug has the potential to prevail over some challenges related to steroid treatment of Duchenne muscular dystrophy. To reduce side effects such as growth stunting and steroid-induced osteoporosis can have a significant impact on the quality of life of patients with Duchenne muscular dystrophy, a statement from CureDuchenne founder and CEO Debra Miller said.
AGAMREE is a corticosteroid that may be prescribed to patients at least two years old who have Duchenne muscular dystrophy. FDA’s approval of the drug was based on a series of studies conducted by ReveraGen Biopharma, which showed that young boys who were treated with vamorolone showed comparable efficacy with other steroids sold in the market. The study also revealed that vamorolone can help reduce the incidence of adverse events related to bone health.
AGAMREE will be available in the US, Canada, and Mexico by the first quarter of 2024.
In 2021, Jeffrey Goffman began his role as CEO of Satellite Healthcare in San Jose, California. One of Jeffrey Goffman’s achievements has be
One GI Continues Strategic Push into Eastern US
Jeffrey Goffman has driven operations at Satellite Healthcare in San Jose, California, as chief executive office since 2021. When he is not supporting the Satellite Healthcare mission of improving the lives of those living with kidney disease, Jeffrey Goffman works as the vice chairman of One GI. The gastroenterology management services provider One GI announced a new partnership with Loudoun…
View On WordPress
Satellite Healthcare Opens Hawaiian High-Risk Nephrology Facility
As the CEO of Satellite Healthcare since 2021, Jeffrey Goffman strives to provide quality nephrology care, especially for high-risk patients. In 2022, Jeffrey Goffman opened Hawai‘i Kidney Care in Kuakini, Hawaii, to provide outpatient nephrology and dialysis services to residents. Hawai‘i Kidney Care fulfills multiple purposes, emphasizing nephrology care for patients with kidney disease and…
View On WordPress
Partnership Aims to Improve Kidney Care
In 2021, Jeffrey Goffman began his role as CEO of Satellite Healthcare in San Jose, California. One of Jeffrey Goffman’s achievements has been creating a partnership between the National Nephrology Alliance (NNA), a Satellite affiliate, and Nephrology Associates Medical Group (NAMG). The NNA, a managing organization, partnered with NAMG to expedite aspects of nephrology practices not involved…
View On WordPress
The National Nephrology Alliance
The CEO of Satellite Healthcare, Jeffrey Goffman, oversees programs and services to improve the quality of life and assist people with kidney disease. Jeffrey Goffman also led Satellite Healthcare in a landmark partnership with Nephrology Associates Medical Group (NAMG) to implement value-based care programs and optimize clinical and business goals through its satellite’s affiliate, the National…
View On WordPress